Toll-like receptor agonists promote the formation of tertiary lymphoid structure and improve anti-glioma immunity
Neuro-Oncology · 2025
DOI: 10.1093/neuonc/noae167 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Shaoping Shen und 13 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Neurological Diseases, Center of Brain Tumor, Beijing Institute for Brain Disorders and Beijing Key Laboratory …. Hauptthemen laut MEDLINE: Glioma, Tertiary Lymphoid Structures, Tumor Microenvironment, Brain Neoplasms. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Capital Health Research and Development of Special Fund, National Natural Science Foundation of China, Peking University Clinical Scientist Training Program.
Abstract (Originalsprache)
Background
Glioma, characterized by limited lymphocytic infiltration, constitutes an “immune-desert” tumor displaying insensitivity to various immunotherapies. This study aims to explore therapeutic strategies for inducing tertiary lymphoid structure (TLS) formation within the glioma microenvironment (GME) to transition it from an immune resistant to an activated state.
Methods
TLS formation in GME was successfully induced by intracranial administration of Toll-like receptor (TLR) agonists (OK-432, TLR2/4/9 agonist) and glioma antigens (i.c. αTLR-mix). We employed staining analysis, antibody neutralization, single-cell RNA sequencing (scRNA-Seq), and BCR/TCR sequencing to investigate the underlying mechanisms of TLS formation and its role in anti-glioma immunity. Additionally, a preliminary translational clinical study was conducted.
Results
TLS formation correlated with increased lymphocyte infiltration in GME and led to improved prognosis in glioma-bearing mice. In the study of TLS induction mechanisms, certain macrophages/microglia and Th17 displayed markers of “LTo” and “LTi” cells, respectively, interaction through LTα/β-LTβR promoted TLS induction. Post-TLS formation, CD4 + and CD8 + T cells but not CD19 + B cells contributed to anti-glioma immunity. Comparative analysis of B/T cells between brain and lymph node showed that brain B/T cells unveiled the switch from naïve to mature, some B cells highlighted an enrichment of class switch recombination (CSR)-associated genes, V gene usage, and clonotype bias were observed. In related clinical studies, i.c. αTLR-mix treatment exhibited tolerability, and chemokines/cytokines assay provided preliminary evidence supporting TLS formation in GME.
Conclusions
TLS induction in GME enhanced anti-glioma immunity, improved the immune microenvironment, and controlled glioma growth, suggesting potential therapeutic avenues for treating glioma in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Clinical Research Center for Neurological Diseases, Center of Brain Tumor, Beijing Institute for Brain Disorders and Beijing Key Laboratory of Brain Tumor, Beijing, China.
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
- Department of Neurosurgery, China-Japan Friendship Hospital, Beijing, China.
- Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
- Capital Medical University, Beijing, China.
- Department of Neurosurgery, Peking University Third Hospital, Peking University, Beijing, China.
ORCID-Profile: Song Lin
Förderung
- Capital Health Research and Development of Special Fund
- National Natural Science Foundation of China
- Peking University Clinical Scientist Training Program
Zitieren
APA
Shen, S., Cui, Y., Li, M., Yu, K., Zhu, Q., Zhang, X., Shen, W., Li, H., Jiang, H., Li, M., Wang, X., Zhao, X., Ren, X., & Lin, S. (2025). Toll-like receptor agonists promote the formation of tertiary lymphoid structure and improve anti-glioma immunity. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae167
Vancouver
Shen S, Cui Y, Li M, Yu K, Zhu Q, Zhang X, et al. Toll-like receptor agonists promote the formation of tertiary lymphoid structure and improve anti-glioma immunity. Neuro-Oncology. 2025. doi:10.1093/neuonc/noae167
BibTeX
@article{Shen2025,
author = {Shen, Shaoping and Cui, Yong and Li, Mingxiao and Yu, Kefu and Zhu, Qinghui and Zhang, Xiaokang and Shen, Weicheng and Li, Haoyi and Jiang, Haihui and Li, Ming and Wang, Xijie and Zhao, Xuzhe and Ren, Xiaohui and Lin, Song},
title = {Toll-like receptor agonists promote the formation of tertiary lymphoid structure and improve anti-glioma immunity},
journal = {Neuro-Oncology},
year = {2025},
doi = {10.1093/neuonc/noae167}
}
EUVIMED